Literature DB >> 2350576

Interleukin-6 enhances murine megakaryocytopoiesis in serum-free culture.

K Koike1, T Nakahata, T Kubo, T Kikuchi, M Takagi, A Ishiguro, K Tsuji, K Naganuma, A Okano, Y Akiyama.   

Abstract

We investigated the effect of interleukin-6 (IL-6) on murine megakaryocytopoiesis in a serum-free culture system. The addition of IL-6 to a culture containing interleukin-3 (IL-3) resulted in a significant increase in the number of megakaryocyte colonies by bone marrow cells of normal mice. The megakaryocytic progenitors that survive exposure to 5-fluorouracil (5-FU) exhibited a more significant response to IL-6 and IL-3. Polyclonal anti-IL-6 antibody neutralized the stimulatory effect of IL-6 on megakaryocyte colony growth supported by IL-3. Delayed addition experiments and replating experiments of blast cell colonies showed that megakaryocytic progenitors are supported by IL-3 in the early stage of the development but require IL-6 for their subsequent proliferation and differentiation. In addition, IL-6 increased the size of megakaryocytes in granulocyte-macrophage-megakaryocyte colonies. The combination of granulocyte colony-stimulating factor or granulocyte-macrophage colony stimulating factor with IL-3 resulted in an increase in the granulocyte-macrophage colony growth of bone marrow cells of 5-FU-treated mice or normal mice, respectively, but had little effect on the enhancement of pure and mixed megakaryocyte colony growth. These results suggest that IL-6 plays an important role in murine megakaryocytopoiesis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2350576

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

Review 1.  Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody.

Authors:  K Yoshizaki; N Nishimoto; M Mihara; T Kishimoto
Journal:  Springer Semin Immunopathol       Date:  1998

2.  Control of megakaryocyte expansion and bone marrow fibrosis by lysyl oxidase.

Authors:  Alexia Eliades; Nikolaos Papadantonakis; Ajoy Bhupatiraju; Kelley A Burridge; Hillary A Johnston-Cox; Anna Rita Migliaccio; John D Crispino; Hector A Lucero; Philip C Trackman; Katya Ravid
Journal:  J Biol Chem       Date:  2011-06-10       Impact factor: 5.157

Review 3.  Anti-interleukin 6 receptor antibody treatment in rheumatic disease.

Authors:  N Nishimoto; T Kishimoto; K Yoshizaki
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 4.  IL-6: from laboratory to bedside.

Authors:  Tadamitsu Kishimoto
Journal:  Clin Rev Allergy Immunol       Date:  2005-06       Impact factor: 8.667

Review 5.  Interleukin-6 in clinical medicine.

Authors:  J Bauer; F Herrmann
Journal:  Ann Hematol       Date:  1991-06       Impact factor: 3.673

Review 6.  The paradigm of IL-6: from basic science to medicine.

Authors:  Tetsuji Naka; Norihiro Nishimoto; Tadamitsu Kishimoto
Journal:  Arthritis Res       Date:  2002-05-09

7.  Designer cytokine hyper interleukin 11 (H11) is a megakaryopoietic factor.

Authors:  Hanna Dams-Kozlowska; Eliza Kwiatkowska-Borowczyk; Katarzyna Gryska; Andrzej Mackiewicz
Journal:  Int J Med Sci       Date:  2013-07-09       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.